WO2025045185 - ARYL OR HETEROARYL SUBSTITUTED CARBAMATE COMPOUND AND DERIVATIVE AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/045185
Publication Date
06.03.2025
International Application No.
PCT/CN2024/115748
International Filing Date
30.08.2024
Title **
[English]
ARYL OR HETEROARYL SUBSTITUTED CARBAMATE COMPOUND AND DERIVATIVE AND USE THEREOF
[French]
COMPOSÉ CARBAMATE SUBSTITUÉ PAR ARYLE OU HÉTÉROARYLE, DÉRIVÉ ET UTILISATION ASSOCIÉE
[Chinese]
芳基或杂芳基取代的氨基甲酸酯类化合物及其衍生物和用途
Applicants **
SHENZHEN ZHONGGE BIOLOGICAL TECHNOLOGY CO., LTD.
Inventors
ZHAO, Liyu
CAO, Bin
MA, Nannan
CHEN, Zhaoqiang
MA, Jin
XIE, Dewei
YANG, Yuwen
DOU, Guosheng
WANG, Shaohui
CHEN, Bin
ZHANG, Peiyu
WEN, Shuhao
Priority Data
202311128222.7
31.08.2023
CN
202411118554.1
14.08.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3041 | |
| EPO | Filing, Examination, Granting | 24528 | |
| Japan | Filing, Examination, Granting | 2793 | |
| South Korea | Filing, Examination, Granting | 3437 | |
| USA | Filing, Examination, Granting | 8190 |
Total:
41,989
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present application relates to a compound of formula (I), a pharmaceutical composition comprising the compound, and a use of the pharmaceutical composition for treating and/or preventing diseases, disorders or conditions associated with AMPK kinase.[French]
La présente invention concerne un composé de formule (I), une composition pharmaceutique comprenant le composé, et une utilisation de la composition pharmaceutique pour le traitement et/ou la prévention de maladies, de troubles ou d'états associés à l'AMPK kinase.[Chinese]
涉及式(I)的化合物，包含所述化合物的药物组合物，以及使用所述药物组合物治疗和/或预防与AMPK激酶相关的疾病、障碍或病症的用途。